Document Detail

Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells.
MedLine Citation:
PMID:  14767525     Owner:  NLM     Status:  MEDLINE    
The present study investigated a correlation between expression of Bcl-2 family members, Bax and Bcl-2 (the Bax/Bcl-2 ratio values) in B-CLL cells in vivo and the response of these cells to chemotherapy. Western blot technique combined with videodensitometry was used for Bax and Bcl-2 determination in homogenate, nuclear and postnuclear fractions of mononuclear cells isolated from peripheral blood of B-CLL patients treated with cladribine alone (C), and in combination with cyclophosphamide (CC) or mitoxantrone and cyclophosphamide (CMC). The Bax/Bcl-2 ratio values were changed in B-CLL cells originated from blood samples of patients treated by the three therapy protocols, and was the most elevated in the case of CMC treatment. High degree of B-CLL cell apoptosis induction with cladribine combined with mitoxantrone and cyclophosphamide was confirmed by DNA fragmentation and an appearance of apoptotic morphology among leukemic cells from the blood of patients treated with this form of combined therapy.
Agnieszka Kobylinska; Jerzy Z Blonski; Malgorzata Hanausek; Zbigniew Walaszek; Tadeusz Robak; Zofia M Kilianska
Related Documents :
7756635 - Bcl-2 is expressed in neurons that survive focal ischemia in the rat.
15793875 - Apoptosis of human gastric cancer sgc-7901 cells induced by mitomycin combined with sul...
19463775 - Deficient activation of bak and bax confers resistance to gemtuzumab ozogamicin-induced...
11227215 - Bcl-2 protects neuronal cells against taxol-induced apoptosis by inducing multi-nucleat...
23656785 - K562 cell proliferation is modulated by plcβ1 through a pkcα-mediated pathway.
23515105 - Differentiation of human neural progenitor cells in functionalized hydrogel matrices.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Oncology reports     Volume:  11     ISSN:  1021-335X     ISO Abbreviation:  Oncol. Rep.     Publication Date:  2004 Mar 
Date Detail:
Created Date:  2004-02-09     Completed Date:  2004-10-07     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9422756     Medline TA:  Oncol Rep     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  699-705     Citation Subset:  IM    
Department of Cytobiochemistry, University of Lodz, 90-237 Lodz, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antineoplastic Agents / administration & dosage
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Blotting, Western
Cell Nucleus / metabolism
Cladribine / administration & dosage*
Cyclophosphamide / administration & dosage*,  therapeutic use
DNA Fragmentation
Electrophoresis, Polyacrylamide Gel
Leukemia, B-Cell / drug therapy*
Leukocytes, Mononuclear / metabolism
Middle Aged
Mitoxantrone / administration & dosage*
Proto-Oncogene Proteins / metabolism*
Proto-Oncogene Proteins c-bcl-2 / metabolism*
Subcellular Fractions
bcl-2-Associated X Protein
Reg. No./Substance:
0/Antineoplastic Agents; 0/Antineoplastic Agents, Alkylating; 0/BAX protein, human; 0/Proto-Oncogene Proteins; 0/Proto-Oncogene Proteins c-bcl-2; 0/bcl-2-Associated X Protein; 4291-63-8/Cladribine; 50-18-0/Cyclophosphamide; 65271-80-9/Mitoxantrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Combining flavopiridol with various signal transduction inhibitors.
Next Document:  Correlation among loss of heterozygosity, promoter methylation and protein expression of MLH1 in lar...